Attention Deficit Hyperactivity Disorder (ADHD) News and Research

RSS

Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral).

Learning Lab of Brentwood to present free seminar on ADHD in Brentwood

The Learning Lab of Brentwood will present a free seminar, ADHD Kids: Getting Along Socially, on Thursday February 18 from 12:00-1:30 PM at the Maryland Farms YMCA in Brentwood.

12 Feb 2010

New sensory tools for younger children

The recent results of the National Survey of Children's Health showed roughly 1 in 90 US children are affected by Autism Spectrum Disorder (ASD). Add to this the gamut of other disorders (Attention Deficit Disorder (ADD/ADHD), Anxiety disorders, Sensory Processing Disorder (SPD), etc.) our children can be faced with, and it isn't surprising that an increasing number of special needs children are in our classrooms.

11 Feb 2010

LDDI releases biomonitoring report on environmental neurotoxins in health affected community

The Learning and Developmental Disabilities Initiative (LDDI) today released the first-ever biomonitoring report identifying toxic chemical pollution in people from the learning and developmental disability community.

5 Feb 2010

Anomalies causing motivational deficiencies may also cause ADHD

Until now, attention-deficit/hyperactivity disorder (ADHD) was related to alterations in the brain affecting attention and cognitive processes. Researchers at Universitat Autònoma de Barcelona and the Vall d'Hebron University Hospital for the first time have discovered anomalies in the brain's reward system related to the neural circuits of motivation and gratification. In children with ADHD, the degree of motivation when carrying out an activity is related to the immediacy with which the objectives of the activity are met. This would explain why their attention and hyperactivity levels differ depending on the tasks being carried out.

4 Feb 2010

Regular physical activity prevents chronic illness: Surgeon General urged to make outdoor time a health priority

National Wildlife Federation (NWF), more than 200 health, conservation, youth, and other organizations, and 16,300 Americans are urging the new surgeon general to make time outdoors a health priority for children.

4 Feb 2010

Researchers discover anomalies that cause lack of motivation in ADHD children

3 Feb 2010

Is there a link to rising rates of autism, ADHD and other learning and developmental disabilities?

Jeff Sell, father of twin sons with autism ,Vice President for Policy at the Autism Society; Maureen H. Swanson, Healthy Children Project Coordinator, Learning Disabilities Association of America; Larry Silver MD, author of the Understanding and Coping with Your Child's Learning Disabilities; and others will join Andy Igrejas, National Campaign Director of the Safer Chemicals, Healthy Families Campaign on a national telephone news briefing for the release of Mind, Disrupted: How Toxic Chemicals May Affect How We Think and Who We Are, produced by the Learning and Developmental Disabilities Initiative (LDDI).

3 Feb 2010

Shire announces the Canadian availability of VYVANSE prodrug therapy for ADHD treatment

Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire plc, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.

2 Feb 2010

BioBehavioral Diagnostics completes $10M Series B financing round

BioBehavioral Diagnostics (BioBDx), a privately held company which manufactures and markets the Quotient™ ADHD System, a tool that aids in the objective and accurate assessment of attention-deficit hyperactivity disorder (ADHD), announced today the first close of a $10 million Series B financing.

1 Feb 2010

New research suggests lead may trigger attention-deficit/hyperactivity disorder

ADHD, or attention-deficit/hyperactivity disorder, is among the costliest of behavioral disorders. Its combination of inattention, impulsivity and hyperactivity leads to accidental injuries, school failure, substance abuse, antisocial behavior and more. Yet despite nearly a century of study, the disorder's roots remain mysterious.

29 Jan 2010

Phthalate exposure can affect child's neurobehavioral development, says study

A new study led by Mount Sinai researchers in collaboration with scientists from Cornell University and the U.S. Centers for Disease Control and Prevention, has found higher prenatal exposure to phthalates-manmade chemicals that interfere with hormonal messaging-to be connected with disruptive and problem behaviors in children between the ages of 4 and 9 years.

28 Jan 2010

Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD

Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses. The trial was initiated in 2009 and was a proof-of-concept, open-label study in children 6 to 12 years of age, assigned to one of four doses over a six-week treatment period, after 2-5 weeks' titration.

27 Jan 2010

Ambidextrous children more likely to have ADHD symptoms

Children who are mixed-handed, or ambidextrous, are more likely to have mental health, language and scholastic problems in childhood than right- or left-handed children, according to a new study published today in the journal Pediatrics.

25 Jan 2010

Vaccination for children: Pros and cons

ProCon.org, a nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, created the new website http://vaccines.procon.org to explore the core question "Should any vaccines be required for children?"

23 Jan 2010

Physicians take measures to treat ADHD on college campuses across the country

In college, students with attention deficit/hyperactive disorder face an array of challenges—long days and nights of classes, studying and activities, all of which require increasing amounts of concentration.

22 Jan 2010

Efficacy of neurofeedback in treating ADD/ADHD

On January 22, the Potomac Institute for Policy Studies will present a guest lecture by Don DuRousseau, founder and CEO of Human Bionics LLC, a neurotechnology company specializing in brain-computer interface (BCI) systems. Mr. DuRousseau will explore the use of neurotechnology techniques, including the increasingly popular neurofeedback, as a treatment for ADD/ADHD.

21 Jan 2010

One-third of parents give primary schools an ‘A’; less than one-fourth give secondary schools an ‘A’

School psychologists, counselors and social workers are often the first line of support for children with behavioral, emotional or family problems. Problems can range from attention deficit disorder and homelessness to depression and bullying all of which can make academic success a challenge.

21 Jan 2010

ABC publishes Pycnogenol monograph

The nonprofit American Botanical Council (ABC) has just published a monograph summarizing selected scientific and clinical studies of Pycnogenol®, a patented dietary ingredient from French maritime pine bark.

21 Jan 2010

Learning Lab of Brentwood conducts a series of monthly presentations on ADHD

Are you concerned that your child has ADHD? Maybe you're not sure exactly what the signs are. Perhaps you are against medicating your child. According to the American Academy of Pediatrics, "ADHD is the most commonly diagnosed behavioral condition in children, affecting approximately 6% to 9% of the school-aged population.

19 Jan 2010

Curemark retains Rubenstein Public Relations

Curemark, a drug research and development company that focuses on the treatment of neurological diseases, has retained Rubenstein Public Relations to help raise national, regional, and industry awareness of the organization's research, treatments and founder, Dr. Joan Fallon. Curemark is developing an autism treatment that will be one of the first to address the underlying physiology of autism.

12 Jan 2010